


Immunotoxicology Specialty Section Newsletter



2003 - 2004

Executive Committee

President

Dr. Tom Kawabata

Vice President

Dr. Bob Luebke

Vice President-Elect

Dr. Ken Hastings

Secretary-Treasurer

Dr. Steve Pruitt

Councilor/Past President

Dr. Robert House

Senior Councilor

Dr. Paige Lawrence

Councilor

Dr. Jeanine Bussiere

Student Representative

In transition - TBA

The Immunotoxicology Specialty Section Newsletter is published 3 times/year (May, August and November). If you would like to share a book review, meeting report, interesting web site or any other item of interest with members of the Specialty Section, please send it to us by the middle of the month preceding the planned publication date. All comments on, or suggestions for, the newsletter are welcome.

Stephen B. Pruitt, Ph.D., Editor
Department of Cellular Biology and Anatomy
LSU Health Sciences Center
1501 Kings Highway
Shreveport, LA 71130
Tel. (318) 675-4386 Fax (318) 675-5889
spruet@LSUHSC.EDU

Jean F. Regal, Associate Editor
Department of Pharmacology
10 University Dr.
University of Minnesota
Duluth, Minnesota 55812
Tel. (218) 726-8950 Fax (218) 726-7906
jregal@d.umn.edu

Typesetting provided by Brenda House.

President's Message

Thomas Kawabata

Greetings Immunotoxicology Specialty Section Members,

Hope you had a good summer. For this newsletter, I would like to encourage all members take part in future Specialty Section activities. This includes students to senior colleagues whom have not had a chance to participate in some of the ISS activities.

Here are some of the reasons that I've heard or used in the past not to get involved. After each reason, I've noted why you should get involved (in italics).

- 1 I've tried to sign up for the committees at the business meetings and all of the slots were filled.

As announced at our business meeting at the last SOT meeting, we are developing ISS goals and specific action plans. GOOD NEWS, we plan to develop more committees to address each of the action plans. A draft list will be sent out to the ISS this fall and finalized by the next newsletter. Please sign up for these committees.

- 2 I know very little about ISS and SOT policies and procedures. I'll let the "old guys" handle it.

You got to start sometime and you will be one of the "old guys" sooner than you think. We will try to setup the committees so that veterans are mixed with rookies. It helps bring in fresh ideas, allow you to meet fellow specialty section members and allow you to learn Specialty Section and SOT policies and procedures.

- 3 I'm just starting my career and too busy generating preliminary data and writing grants to get involved at this time.

Although you are very busy now, you will be even busier and over committed in the future. Thus, NOW is a good time. Committee participation is an excellent way to network with others in the field. Who knows, it may lead to future collaborations and better career opportunities.

WHAT CAN YOU DO?

- 1 We plan to send out a questionnaire to the ISS in September. Please respond and add any suggestions. The information obtained from this questionnaire will be included in our goals.

- 2 We plan to send out a draft of the goals and specific action plans this fall. Please carefully review and promptly send in your comments.

- 3 The final list of goals / action steps will be sent out in our next newsletter and will be discussed more at the 2004 ISS business meeting. If you see a specific goal / action step that is of interest, please volunteer for that committee.

Remember, like the immune response our specialty section is dependent on numerous components to function. So all you T cells out there, we need your HELP (not suppression).

*Best Regards,
Tom Kawabata*

President, Immunotoxicology Specialty Section (2003-2004)

Program Committee Report

Submitted by Ken Hastings

Folks: its never too early to begin planning for the next meeting, which in this case is New Orleans in 2005. Please put on your thinking caps (if you haven't already): let's put together a good (make that great) package of proposals when we meet in Baltimore! If you have ideas, please pass them on to me or anyone else on the Program Committee (Mitch Cohen, Dori Germolec, Bob Luebke, Ian Gilmour, Mitzi Nagarkatti, Greg Ladics, Peyton Myers, Frank Gerberick, Jean Regal, Ian Kimber, or Susan McKarns). Remember: it's always best to have your proposal put together *before* the annual meeting. I'm glad to help out!

Program Committee for 2004 Contact Information

Ken Hastings
Chair (VP Elect)

Mitch Cohen
(cohenm@env.med.nyu.edu)

Dori Germolec
(germolec@niehs.nih.gov)

Bob Luebke
(luebke.robert@epa.gov)

Ian Gilmour
(gilmour.ian@epa.gov)

Mitzi Nagarkatti
(mnagark@hsc.vcu.edu)

Greg Ladics
(gregory.s.ladics@usa.dupont.com)

Peyton Myers
(lmyers@cdc.gov)

Frank Gerberick
(gerberick.gf@pg.com)

Jean Regal
(jregal@d.umn.edu)

Ian Kimber
(ian.kimber@syngenta.com)

Susan McKarns
(mckarnss@mail.nih.gov)

Treasurer's Report

Immunotoxicology Section July 2002 - June 2003



Ordinary Income/Expense	
Contributions	100
Dues - '03	2,685
Student Dues - '03	-
Grants - Food Safety	-
Grants - Mechanisms	-
Misc. Income	-
Registrat'n	3,758
Interest	177
Total Income	6,720
Expense	
Awards - Sections	500
Plaques	508
Ballot	-
audiovisual-Utah	2,151
Prog. Comm. Breakfast	114
Newsletter	200
Reception	2,558
Steno/Clerical	-
Symposia	-
Web Development	-
Total Expense	6,031
Excess (Deficiency) of Revenue over Expenses	688
Net Assets Beginning of Year	3,022
Transfers from General Fund	-
Net Assets Beginning of Year After Transfers	3,022
Net Assets End of Year	3,711

Regulatory Committee Report

Submitted by Ken Hastings

The European Centre for Ecotoxicology and Toxicology of Chemicals has published a document entitled *Contact Sensitisation: Classification According to Potency* (Technical Report No. 87; April, 2003) which can be obtained from the secretariat (see www.ecetoc.org). This document deals with the difficult problem of classifying contact allergens according to relative potency and thresholds for induction and elicitation. Of note is the conclusion that the murine local lymph node assay (LLNA) should be considered the method of choice of determining skin sensitizing potential for the purpose of categorization. The document also considers results obtained using the guinea pig maximization test and the Buehler occluded patch test and concludes “[these data] can, if interpreted judiciously, provide information of value in assessment of skin sensitization potency.” The document proposes the following descriptors be used to classify potency: ‘extreme’, ‘strong’, ‘moderate’, or “weak”. This is an interesting and useful guide to using these assays for risk assessment. While checking out the ECETOC website, you might want to look at some other documents that have been published on immunotoxicology (Monographs 10, 14, 19, 21, 29, 32; Technical Reports 77, 78), as well as others of interest.

On a related note, Dee Sailstad provided the following website address for information on the LLNA:

iccvam.niehs.nih.gov/methods/llna.htm

Preview Book Announcement

Preview Announcement of an important new textbook in immunotoxicology

Title: Developmental Immunotoxicology

Editor: Steve Holladay

The textbook will begin with two chapters that provide an overview of development of the rodent and human immune systems. These will be followed by a chapter of risk assessment perspectives for developmental immunotoxicology, and four chapters that examine utility of different animal models for studying developmental immunotoxicology. A third section of the book will consist of five chapters that review different classes of developmental immunotoxicants and associated postnatal immune suppression. The forth section will then examine developmental immunotoxicant exposure and exacerbated immune responses, including asthma and autoimmune disease. A final section will consider relationships between developmental neurotoxicity and postnatal immune deficits, and maternal malnutrition and impaired postnatal immune responses.

The publisher will be Taylor and Francis, with a publishing date of 2004.

New Immunotoxicology Conference Held in Montana

The 2003 Northwest Immunotoxicology Conference was held on August 15th and 16th at the University of Montana's Salmon Lake Conference Center. This event was sponsored by the University of Montana's Center for Environmental Health Sciences (CEHS), with generous funding provided by NSF-EPSCoR, NCRR and the CEHS. The conference brought together scientists in the northwest region that are currently exploring the effects of synthetic and natural chemicals on the immune system. Immunotoxicologists from Oregon State University, University of Washington, Washington State University, Bastyr University's Research Institute and the University of Montana were in attendance. The conference was held over two days, the first day focused on compounds that suppress immunity and included presentations by Dr. Nancy Kerkvliet (OSU), Dr. B. Paige Lawrence (WSU), and Dr. David Shepherd (UM). The second day concentrated on various xenobiotics that enhance immunity and included presentations by Dr. Andrij Holian (UM), Dr. Jean Pfau (UM), and Dr. Cynthia Wenner (Bastyr).

The combination of formal presentations and informal break out sessions served to facilitate collaborations and discussion among principal investigators, postdocs, graduate students and research staff. It is the hope of the conference organizers, Dr. Andrij Holian (aholian@selway.umt.edu) and Dr. David Shepherd (shepherd@selway.umt.edu), that this meeting will grow in size and scope over the next few years to attract other immunotoxicologists from the West coast, or perhaps even from across the country. For more information, please contact the conference organizers at the University of Montana.

Best Presentations by a Student and by a Post-doctoral Trainee Awards

The award requirements are submission of a complete written version (including all graphs and tables) of an Immunotoxicology presentation to be made at the SOT annual meeting. This presentation is to be accompanied by a Letter of Nomination from the Student's or Post-doctoral Fellow's advisor. Electronic submissions are strongly encouraged. No manuscripts will be accepted. Winners will receive a plaque and cash award.

The deadline for submission is February 6, 2004.

Please submit nominations to:

Dr. Paige Lawrence
Washington State University
College of Pharmacy
Washington State University
Department of Pharmaceutical Sciences
Pullman, WA 99164-6534
USA
Email: bpl@mail.wsu.edu

As some of you may recall, we did not award a Best Immunotoxicology Paper of the Year at our 2003 meeting. This came as a disappointment to many people, especially because some excellent papers were published in 2002. The solution to this problem rests with the membership. If you read an exceptionally good paper, please take the time to nominate it for this award.

To assist with this process, some changes have been made in the criteria for Best Immunotoxicology Paper of the Year Award. The two major changes pertain to the scope and time frame. This award is no longer restricted to papers published in Toxicological Sciences or Toxicology and Applied Pharmacology. **You may nominate immunotoxicology papers published in any peer-reviewed journal.** To

*Keep Your
Eyes Peeled
for a
Great
Immunotoxicology
paper and
Nominate It For An Award!*

address concerns about the lag between acceptance for publication and actual publication, we have extended the dates that define eligibility. **Papers published between July 1, 2002 and December 31, 2003 will be eligible for nomination.** An additional change is that authors may no longer nominate their own papers. The deadline for nominating a paper is January 31, 2004.

Nominations may be submitted via email to bpl@wsu.edu. The nomination for this award should provide the full citation of the paper and a short description of the value of the research

to the field of Immunotoxicology. Nominations will be evaluated by the members of the Awards Committee, and the winner will be announced at the Immunotoxicology Specialty Section business meeting, held at the SOT annual meeting in Baltimore, MD.

POSITION ANNOUNCEMENTS

POSTDOCTORAL POSITION

NHEERL, U.S. EPA, Research Triangle Park, NC

3-yr Term appt - GS9-GS13 (\$38,588 - \$72,746) depending on experience & qualifications

Application deadline October 31.

The purpose is to develop a rodent model of food allergy that could be used to assess the allergenicity of genetically modified foods and answer specific concerns regarding cross reactivity, dose response, relative potency, aggregate risk from multiple routes of exposure, sensitive populations, and structure activity. Research may develop along a variety of lines including explorations of the mechanisms underlying the development of oral tolerance, genetic susceptibility, adjuvancy, the potential role of concomitant exposures, etc. The project provides the opportunity to work in a brand new facility with a group that has had significant success in the development of rodent models of respiratory allergy as well as infectious diseases.

For more details see:

<http://www.epa.gov/nheerl/postdocs/>
(Experimental Toxicology Division 06/05/01-35) or contact
MaryJane Selgrade
selgrade.maryjane@epa.gov

POSTDOCTORAL POSITION

A postdoctoral position is available through a cooperative training agreement with the University of North Carolina to work with investigators in the Immunotoxicology Branch, Experimental Toxicology Division, National Health and Environmental Effects Research Laboratory, US EPA, Research Triangle Park, NC. The focus of this research is to assess the potential sensitivity of the developing immune system to toxicant-induced immunosuppression. The goal of this research is to apply a panel of *in vivo*, *ex vivo* and *in vitro* assays to determine whether the developing (i.e., prenatal, neonatal and/or post-weaning/juvenile periods of development) immune system of the rat exhibits increased susceptibility to immunosuppressive chemicals compared to the adult.

For more information contact:

Ralph J. Smialowicz
B143-04
U.S. Environmental Protection Agency
Research Triangle Park, NC 27711
Phone: (919) 541-5776
FAX: (919) 541-3538
smialowicz.ralph@epa.gov

POSTDOCTORAL POSITION

β 2-Adrenergic Receptor Signaling and Cytokine Gene Regulation in CD4 $^{+}$ T-Cell Subsets

A full-time postdoctoral research position is available in the laboratory of Dr. Virginia Sanders at The Ohio State University in the Department of Molecular Virology, Immunology & Medical Genetics. The research position will be funded by NIH grants, including a NIAID-funded Training Program in Integrative Immunobiology. The primary area of research involves β 2-adrenergic receptor signaling and cytokine gene regulation in CD4 $^{+}$ T-cell subsets. Requirements for application include a Ph.D. degree in Immunology, Cell Biology, Molecular Biology, Pharmacology, Neuroscience, or a closely related field, as well as research experience in cell signaling, gene expression, and/or T-cell immunology.

Please send a letter of research interest, CV, and the names of three references to:

Virginia M. Sanders, Ph.D.
Dept. of Molecular Virology,
Immunology & Medical Genetics
The Ohio State University
333 W. 10th Avenue
Columbus, OH 43210
sanders.302@osu.edu

Compiled by Helen Ratajczak

ANYTIME you have a new publication to report, please send it to hratajcz@rdg.boehringer-ingelheim.com
It will be included in the next newsletter.

ASTHMA, ALLERGY AND HYPERSENSITIVITY

Bannon GA, Fu T-J, Kimber I, Hinton DM. Protein digestibility and relevance to allergenicity. *Environ Hlth Persp* 111:1122-1124, 2003.

Dearman RJ, Cumberbatch M, Kimber I. Cutaneous cytokine expression: induction by chemical allergen and paracrine regulation. *J Toxicol Cutan Ocular Toxicol* 22:69-86, 2003.

Gent JF, Ren P, Belanger K, Triche E, Bracken MB, Holford TR, Leaderer BP. Levels of household mold associated with respiratory symptoms in the first year of life in a cohort at risk for asthma. *Environ Health Perspect* 110:A781-786, 2002.

Germolec DR, Kimber I, Goldman L, Selgrade MJK. Key issues for the assessment of the allergenic potential of genetically modified foods: Breakout group reports. *Environmental Health Perspectives* 111:1131-1139, 2003.

Hickman-Davis JM, O'Reilly P, Davis IC, Peti-Peterdi J, Davis G, Young KR, Devlin RB, Matalon S. Killing of *Klebsiella pneumoniae* by human alveolar macrophages. *Am J Physiol Lung Cell Mol Physiol* 282: L944-L956, 2002.

Humphreys NE, Dearman RJ, Kimber I. Assessment of cumulative allergen-activated lymph node cell proliferation using flow cytometry. *Toxicol Sc* 73:80-89, 2003.

Kimber I, Betts CJ, Dearman RJ. Assessment of the allergenic potential of proteins. *Toxicol Let* 140/141:297-302, 2003.

Kimber I, Dearman RJ. What makes a chemical an allergen? *Ann Allergy Asthma Immunol* 90:28-31, 2003.

Ladics GS, Holsapple MP, Astwood JD, Kimber I, Knippels LMJ, Helm RM, Dong W. Workshop overview: approaches to the assessment of the allergenic potential of food from genetically modified crops. *Toxicol Sc* 73:8-16, 2003.

Lambert AL, Trasti FS, Mangum JB, Everitt JI. Effect of preexposure to ultrafine carbon black on respiratory syncytial virus infection in mice. *Toxicol Sc* 72:331-338, 2003.

Lambert AL, Mangum JB, DeLorme MP, Everitt JI. Ultrafine carbon black particles enhance respiratory syncytial virus-induced airway reactivity, pulmonary inflammation, and chemokine expression. *Toxicol Sc* 72:339-346, 2003.

Lim LHK, Bochner BS, Wagner EM. Leukocyte recruitment in the airways: an intravital microscopic study of rat tracheal microcirculation. *Am J Physiol Lung Cell Mol Physiol* 282: L959-L967, 2002.

Selgrade MJK, Kimber I, Goldman L, Germolec DR. Assessment of allergenic potential of genetically modified foods: An agenda for future research. *Environ Health Persp* 111:1140-1141, 2003.

Reviews

Ware LB, Matthay MA. Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair. *Am J Physiol Lung Cell Mol Physiol* 282: L924-L940, 2002.

AUTISM

Anonymous. Global Advisory Committee on Vaccine Safety, 16-17 December 2002. *Weekly Epidemiol Rec* 78:17-20, 2003.

Askalan R, Mackay M, Brian J, et al. Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms. *J Child Neurol* 18:165-170, 2003.

Constantino JN, Todd RD. Autistic traits in the general population: a twin study. *Arch Gen Psychiat* 60:524-530, 2003.

Dobson R. Media misled the public over the MMR vaccine, study says. *BMJ* 326:1107, 2003.

Filipek PA, Juranek J, Smith M, et al. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. *Ann Neurol* 53:801-804, 2003.

Fitzpatrick M. Heavy metal. *Lancet* 361:1664, 2003.

Griffiths PD. Vaccines: back to the future. *Rev Med Virol* 13:69-70, 2003.

Hobson RP, Bishop M. The pathogenesis of autism: insights from congenital blindness. *Philosoph Transact Royal Soc London – Series B: Biol Sc* 358:335-344, 2003.

McCormick MK. The autism “epidemic”: impressions from the perspective of immunization safety review. *Ambul Pediatr* 3:119-120, 2003.

Popke EJ. From anticholinesterase toxicity to Alzheimer’s disease: important interactions of cholinergic and NMDA receptor systems. *Toxicol Sc* 72:185-187, 2003.

Scherer SW, Cheung J, MacDonald JR et al. Human chromosome 7: DNA sequence and biology. *Science* 300:767-772, 2003.

Shao Y, Cuccaro ML, Hauser ER, et al. Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. *Am J Hu Genet* 72:539-548, 2003.

Vincent A, Dalton P, Clover L, et al. Antibodies to neuronal targets in neurological and psychiatric diseases. *Ann NYAS* 992:48-55, 2003.

Reviews

Acosta MT, Pearl PL. The neurobiology of autism: new pieces of the puzzle. *Curr Neurol Neurosci Rep* 3:149-156, 2003.

Bolte ER. The role of cellular secretion in autism spectrum disorders: a unifying hypothesis. *Med Hypoth* 60:119-122, 2003.

McDougle CJ, Stigler KA, Posey DJ. Treatment of aggression in children and adolescents with autism and conduct disorder. *J Clin Psychiatr* 64:16-25, 2003.

Nelson KB, Bauman ML. Thimerosal and autism? *Pediat* 111:674-679, 2003.

Prior M. Is there an increase in the prevalence of autism spectrum disorders? *J Paediat Child Health* 39:81-82, 2003.

White JF. Intestinal pathophysiology in autism. *Exp Biol Med* 228:639-649, 2003.

AUTOIMMUNITY, HYPERSENSITIVITY

Daniels MJ, Selgrade MJK, Doerfler D, Gilmour MI. Kinetic profile of influenza virus infection in three rat strains. *Compar Med* 53:293-298, 2003.

CYTOKINES AND CHEMOKINES

Boutin H, Kimber I, Rothwell NJ, Pinteaux E. The expanding interleukin-1 family and its receptors: do alternative IL-1 receptor/signaling pathways exist in the brain? *Molec Neurobiol* 27:239-248, 2003.

Cumberbatch M, Bhushan M, Dearman RJ, Kimber I, Griffiths CEM. IL-1?-induced Langerhans cell migration and TNF-? production in human skin: regulation by lactoferrin. *Clin Exp Immunol* 132:352-359, 2003.

Islam Z, Pestka JJ. Role of IL-1 (beta) in endotoxin potentiation of deoxynivalenol-induced corticosterone response and leukocyte apoptosis in mice. *Toxicol Sci* 74:93-102, 2003.

Justice JP, Crosby J, Borchers MT, Tomkinson A, Lee JJ, Lee NA. CD4+ T cell-dependent airway mucus production occurs in response to IL-5 expression in lung. *Am J Physiol Lung Cell Mol Physiol* 282: L1066-L1074, 2002.

Pruett, S.B., Fan, R., and Zheng, Q. Acute ethanol administration profoundly alters poly I:C-induced cytokine expression in mice by a mechanism that is not dependent on corticosterone. *Life Sci.* 72:1825-1839, 2003.

Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. *Am J Physiol Lung Cell Mol Physiol* 282: L11453-L1150, 2002.

Zhou J, Meadows GG. Alcohol consumption decreases IL-2-induced NF- κ B activity in enriched NK cells from C57BL/6 mice. *Toxicol Sci* 73:72-79, 2003.

EFFECTS: COMPOUNDS

Afaq F, Adhami VM, Ahmad N. Preventin of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. *Tox Appl Pharmacol* 186:28-37, 2003.

Baskin DS, Ngo H, Didenko VV. Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. *Toxicol Sci* 74:361-368, 2003.

Ernstgard L, Gullstrand E, Lof A, Johanson G. Are women more sensitive than men to 2-propanol and m-xylene vapours? *Occup Environ Med* 59:759-767, 2002.

Gondre-Lewis TA, Hartmann CB, Caffrey RE, McCoy KL. Gallium arsenide exposure impairs splenic B cell accessory function. *Int Immunopharmacol* 3:403-415, 2003.

Harrison MT, Hartmann CB, McCoy KL. Impact of in vitro gallium arsenide exposure on macrophages. *Toxicol Appl Pharmacol* 186:18-27, 2003.

Hébert, P. and Pruitt, S.B. Ethanol suppresses poly I:C-induced activation of natural killer cells primarily by acting on NK cells, not through effects on other cell types. *Alcohol (high priority communication)* 28:75-81, 2002.

Hinton DM, Myers MJ, Raybourne RA, Francke-Carroll S, Sotomayor RE, Shaddock J, Warbritton A, Chou MW. Immunotoxicity of aflatoxin B1 in rats: effects on lymphocytes and the inflammatory response in a chronic intermittent dosing study. *Toxicol Sci* 73:362-377, 2003.

Liu J, Lei D, Waalkes MP, Beliles RP, Morgan DL. Genomic analysis of the rat lung following elemental mercury vapor exposure. *Toxicol Sci* 74:174-181, 2003.

McCue JM, Lazis S, Cohen JJ, Modiano JF, Freed BM. Hydroquinone and catechol interfere with T cell cycle entry and progression through the G1 phase. *Molec Immunol* 39:995-1001, 2003.

Mitchell KA, Lawrence BP. Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) renders influenza virus-specific CD8+ T cells hyporesponsive to antigen. *Toxicol Sci* 74:74-84, 2003.

Muscarella DE, O'Brien KA, Lemley AT, Bloom SE. Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. *Toxicol Sci* 74:66-73, 2003.

Muscarella DE, Bloom SE. Cross-linking of surface IgM in the Burkitt's lymphoma cell line ST486 provides protection against arsenite- and stress-induced apoptosis that is mediated by ERK and phosphoinositide 3-kinase signaling pathways. *J Biol Chem* 278:4358-4367, 2003.

Page TJ, O'Brien S, Holston K, MacWilliams PS, Jefcoate CR, Czuprynski CJ. 7,12-dimethylbenz[a]anthracene-induced bone marrow toxicity is p53-dependent. *Toxicol Sci* 74:85-92, 2003.

Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, Waalkes MP. Metallothionein is a potential negative regulator of apoptosis. *Toxicol Sci* 73: 294-300, 2003.

Van Winkle LS, Gunderson AD, Shimizu JA, Baker GL, Brown CD. Gender differences in naphthalene metabolism and naphthalene-induced acute lung injury. *Am J Physiol Lung Cell Mol Physiol* 282: L1122-L1134, 2002.

Vorderstrasse BA, Bohn A, Lawrence BP. Examining the relationship between impaired host resistance and altered immune function in mice treated with TCDD. *Toxicology* 188:15-28, 2003.

Warbrick EV, Kilgour JD, Dearman RJ, Dugard PH, Kimber I. Inhalation exposure to methylene chloride does not induce systemic immunotoxicity in rats. *J Toxicol Environ Hlth* 66:1207-1219, 2003.

Zhou H-R, Lau AS, Pestka JJ. Role of double-stranded RNA-activated protein kinase R (PKR) in deoxynivalenol-induced ribotoxic stress response. *Toxicol Sci* 74:335-344, 2003.

EFFECTS: ENVIRONMENT

Cao L, Hudson CA, Lawrence DA. Immune changes during acute cold/restraint stress-induced inhibition of host resistance to *Listeria*. *Toxicol Sci* 74:325-334, 2003.

Hamm JT, Chen C-Y, Birnbaum LS. A mixture of dioxins, furans, and non-ortho PCBs based upon consensus toxic equivalency factors produces dioxin-like reproductive effects. *Toxicol Sci* 74:182-191, 2003.

Wagner JG, VanDyken SJ, Wierenga JR, Hotchkiss JA, Harkema JR. Ozone exposure enhances endotoxin-induced mucous cell metaplasia in rat pulmonary airways. *Toxicol Sci* 74:437-446, 2003.

GENETICS AND IMMUNOLOGY

Sabourin CLK, Danne MM, Buxton KL, Rogers JV, Niemuth NA, Blank JA, Babin MC, Casillas RP. Modulation of sulfur mustard-induced inflammation and gene expression by olvanil in the hairless mouse vesicant model. *J Toxicol Cutaneous Ocul Toxicol* 22:125-136, 2003.

MODELS AND METHODS

Dearman RJ, Skinner RA, Humphreys NE, Kimber I. Methods for the identification of chemical respiratory allergens in rodents: comparisons of cytokine profiling with induced changes in serum IgE. *J Appl Toxicol* 23:199-207, 2003.

Kimber I, Dearman RJ, Penninks AH, Knippels LMJ, Buchanan RB, Hammerberg B, Jackson HA, Helm RM. Assessment of protein allergenicity on the basis of immune reactivity: animal models. *Environ Hlth Persp* 111:125-130, 2003.

Kimber I, Dearman RJ, Gerberick GF, Roggeband R, Baskettter DA. Designation of substances as skin sensitising chemicals: a commentary. *Human Exp Toxicol* 22:439-443, 2003.

Logan TP, Shutz M, Schulz SM, Railer R, Ricketts KM, Casillas RP. Application and detection of 14C-HD in two mouse models. *Toxicol Mech Meth* 12:293-300, 2002.

GENERAL IMMUNOTOXICOLOGY

Ashby J, Tinwell H, Lefevre PA, Joiner R, Haseman J. The effect on sperm production in adult Sprague-Dawley rats exposed by gavage to bisphenol A between postnatal days 91-97. *Toxicol Sci* 74:129-138, 2003.

Damstra T. Endocrine Disrupters: The need for a refocused vision. *Toxicol Sci* 74:231-232, 2003.

Daston GP, Cook JC, Kavlock RJ. Uncertainties for endocrine disrupters: Our view on progress. *Toxicol Sci* 74:245-252, 2003.

Golub MS, Hogrefe CE, Germann SL, Lasley BL, Natarajan K, Tarantal AF. Effects of exogenous estrogenic agents on pubertal growth and reproductive system maturation in female rhesus monkeys. *Toxicol Sci* 74:103-113, 2003.

Podojil J, Sanders VM. Mature IgG1 transcription is regulated by CD86 and beta-2-adrenergic receptor stimulation on a B cell. *J Immunol* 170:5143-5151, 2003.

Pruett, S.B., Fan, R., and Zheng, Q. Characterization of glucocorticoid receptor translocation, cytoplasmic I κ B, nuclear NF κ B, and activation of NF κ B in T Lymphocytes Exposed to Stress-Inducible Concentrations of Corticosterone In Vivo. *Int. Immunopharmacol.* 3:1-16, 2003.

Smith WJ, Babin MC, Kiser RC, Casillas RP. Development of medical countermeasures to sulfur mustard vesication. IN: Salem H, Katz S (editors). *Alternative Toxicological Methods, Validated Methods for Meeting the 3R's*. CRC Press, LLC, Boca Raton, Florida, pp 323-328, 2003.

Turner KJ, McIntyre BS, Phillips SL, Barlow NJ, Bowman CJ, Foster PMD. Altered gene expression during rat Wolffian duct development in response to in utero exposure to the antiandrogen Linuron. *Toxicol Sci* 74:114-128, 2003.

Valentovic MA, Minigh J. Pyruvate attenuates myoglobin in vitro toxicity. *Toxicol Sci* 74:345-351, 2003.

Vinson RK, Hales GF. Genotoxic stress response gene expression in the mid-organogenesis rat conceptus. *Toxicol Sci* 74:157-164, 2003.

Wickramaratna JC, Fry BG, Hodgson WC. Species-dependent variations in the in vitro myotoxicity of death adder (*Acanthophis*) venoms. *Toxicol Sci* 74:352-360, 2003.

Zieziulewicz TJ, Unfricht DW, Hadjout N, Lynes MA, Lawrence DA. Shrinking the biologic world – nanobiotechnologies for toxicology. *Toxicol Sci* 74:235-244, 2003.

Reviews

Pruett, S.B. Stress and the immune system. *Pathophysiology*. 9:133-153, 2003.